project id: TCGA-PRAD; case submitter id: TCGA-XK-AAJ3; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.89; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.43; rna integrity number: 8.9; age at index: 56; days to birth: -20604; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1954; age at diagnosis: 20604; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1262.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 1185; days to sample procurement: 0; initial weight: 20.0; sample id: 8b21df1c-2190-4e34-b01f-e9d2e78b8a80; sample submitter id: TCGA-XK-AAJ3-01A; portion id: 89ec235c-683c-40f5-8719-ddb2bf4e7e55; portion submitter id: TCGA-XK-AAJ3-01A-11; slide id: 48c36fdf-232a-49bc-aab5-4b8bfb215743; slide submitter id: TCGA-XK-AAJ3-01Z-00-DX1; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 70.0; percent tumor nuclei: 80.0; section location: TOP;